Loring Wolcott & Coolidge Fiduciary Advisors LLP MA grew its stake in shares of Celgene Corporation (NASDAQ:CELG) by 7.7% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 1,017,180 shares of the biopharmaceutical company’s stock after acquiring an additional 73,107 shares during the period. Celgene Corporation comprises about 2.7% of Loring Wolcott & Coolidge Fiduciary Advisors LLP MA’s holdings, making the stock its 10th biggest position. Loring Wolcott & Coolidge Fiduciary Advisors LLP MA owned about 0.13% of Celgene Corporation worth $137,736,000 at the end of the most recent reporting period.
Several other institutional investors also recently modified their holdings of CELG. Harel Insurance Investments & Financial Services Ltd. purchased a new stake in Celgene Corporation in the 1st quarter worth approximately $118,000. Penserra Capital Management LLC purchased a new stake in Celgene Corporation in the 2nd quarter worth approximately $129,000. Acropolis Investment Management LLC purchased a new stake in Celgene Corporation in the 2nd quarter worth approximately $144,000. Mitsubishi UFJ Securities Holdings Co. Ltd. grew its stake in Celgene Corporation by 47.5% in the 1st quarter. Mitsubishi UFJ Securities Holdings Co. Ltd. now owns 1,180 shares of the biopharmaceutical company’s stock worth $147,000 after acquiring an additional 380 shares during the period. Finally, Rational Advisors LLC purchased a new stake in shares of Celgene Corporation during the 2nd quarter valued at $156,000. Hedge funds and other institutional investors own 79.16% of the company’s stock.
Several analysts have recently issued reports on CELG shares. Canaccord Genuity set a $156.00 price target on shares of Celgene Corporation and gave the stock a “buy” rating in a research report on Thursday, July 27th. Stifel Nicolaus started coverage on shares of Celgene Corporation in a report on Friday, July 28th. They issued a “buy” rating and a $155.00 price objective on the stock. Argus upgraded shares of Celgene Corporation from a “hold” rating to a “buy” rating and boosted their price objective for the stock from $96.93 to $160.00 in a report on Monday, July 31st. Cantor Fitzgerald set a $160.00 target price on shares of Celgene Corporation and gave the company a “buy” rating in a research note on Thursday, July 27th. Finally, Mizuho set a $134.00 target price on shares of Celgene Corporation and gave the company a “buy” rating in a research note on Wednesday, July 26th. One investment analyst has rated the stock with a sell rating, eleven have given a hold rating, nineteen have given a buy rating and two have given a strong buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and an average price target of $139.64.
TRADEMARK VIOLATION WARNING: This report was first posted by Week Herald and is the property of of Week Herald. If you are reading this report on another publication, it was stolen and reposted in violation of United States and international trademark and copyright law. The original version of this report can be viewed at https://weekherald.com/2017/11/14/celgene-corporation-celg-stake-lifted-by-loring-wolcott-coolidge-fiduciary-advisors-llp-ma.html.
Shares of Celgene Corporation (NASDAQ CELG) traded down $1.18 during trading on Tuesday, reaching $101.16. 5,476,000 shares of the company’s stock were exchanged, compared to its average volume of 4,678,545. The company has a current ratio of 3.65, a quick ratio of 3.52 and a debt-to-equity ratio of 1.31. Celgene Corporation has a 12-month low of $94.55 and a 12-month high of $147.17. The company has a market cap of $78,000.00, a P/E ratio of 15.99, a PEG ratio of 0.79 and a beta of 1.79.
Celgene Corporation (NASDAQ:CELG) last issued its quarterly earnings results on Thursday, October 26th. The biopharmaceutical company reported $1.91 earnings per share for the quarter, beating analysts’ consensus estimates of $1.87 by $0.04. The firm had revenue of $3.29 billion during the quarter, compared to the consensus estimate of $3.42 billion. Celgene Corporation had a net margin of 27.36% and a return on equity of 63.80%. The business’s revenue was up 10.2% on a year-over-year basis. During the same period in the prior year, the firm earned $1.58 EPS. analysts forecast that Celgene Corporation will post 6.67 earnings per share for the current year.
In related news, Director Gilla Kaplan sold 9,250 shares of Celgene Corporation stock in a transaction dated Tuesday, September 12th. The shares were sold at an average price of $141.56, for a total transaction of $1,309,430.00. Following the completion of the transaction, the director now directly owns 85,551 shares of the company’s stock, valued at approximately $12,110,599.56. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Terrie Curran sold 1,727 shares of Celgene Corporation stock in a transaction dated Monday, September 25th. The shares were sold at an average price of $143.89, for a total transaction of $248,498.03. Following the transaction, the insider now directly owns 3,925 shares of the company’s stock, valued at $564,768.25. The disclosure for this sale can be found here. Insiders have sold a total of 20,227 shares of company stock valued at $2,843,956 over the last ninety days. 0.95% of the stock is owned by insiders.
About Celgene Corporation
Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.
Receive News & Ratings for Celgene Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene Corporation and related companies with MarketBeat.com's FREE daily email newsletter.